Valneva's Stock Breaks Through Its €2.26 Support, Extending Its Losing Streak

Valneva's Stock Dips Further, Breaking Key Support Level

Valneva's stock fell 2.11% to €2.23 in early afternoon trading, after breaking through its €2.26 support level during the session. The stock failed to recover and provisionally closed below this threshold, a technical marker that has been tested repeatedly since mid-May.

The decline is part of a deeply negative trend: the stock is down 7.17% over the past month and 52.37% over three months. The RSI at 37 indicates selling pressure without a clear oversold signal.

All three moving averages confirm the bearish setup: the price is 10.5% below the MM20 (€2.49), 11.6% below the MM50 (€2.52), and 40.1% below the MM200 (€3.72). The next resistance is at €2.74.

Rapid Increase in Short Positions and Downward Revision of Revenue

According to reviewed statements, three funds now hold a combined 2.37% of the capital in short positions, up from 1.16% a month ago (+1.21 points in thirty days). This rapid increase signals a rise in bearish pressure from institutional investors, though not yet reaching a level of extreme stress on the stock.

On the fundamental side, the first quarter accounts published on May 13 showed a 37% decline in revenue and a net loss of €32.1 million. At that time, the company adjusted its 2026 revenue range to between €135 and €150 million and initiated a plan to reduce operational expenses by 25 to 35%.

The biotech will participate in three investor conferences in June, where it will present its LB6V candidate against Lyme disease, developed in collaboration with Pfizer.